Tranexamic acid: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
imported>Howard C. Berkowitz No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
In [[medicine]], [[tranexamic acid]] is an "inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid." It is similar to, but more potent than [[aminocaproic acid]].<ref name="urlDailyMed: tranexamic acid">{{cite web |url=http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7849 |title=cyklokapron (tranexamic acid) injection, solution |author=Anonymous |authorlink= |coauthors= |date= |format= |work= |publisher=U.S. National Library of Medicine |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=2009-02-19 | In [[medicine]], [[tranexamic acid]] a hemostatic agent approved for hemorrhaging in [[hemophilia]], with unapproved uses in cyanide poisioning, hereditary [[angioedema]], hyperfibrinolysis induced hemorrhage, postsurgical hemorrhage and prevention of hemorrhage from cardiovascular instability after [[coronary artery bypass graft]]. It is an "inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid." It is similar to, but more potent than [[aminocaproic acid]].<ref name="urlDailyMed: tranexamic acid">{{cite web |url=http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7849 |title=cyklokapron (tranexamic acid) injection, solution |author=Anonymous |authorlink= |coauthors= |date= |format= |work= |publisher=U.S. National Library of Medicine |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=2009-02-19}}</ref> It is also used to treat acquired [[angioedema]] due to deficiency of [[complement C1 inhibitor protein]]. | ||
==References== | ==References== | ||
Revision as of 21:45, 6 May 2009
In medicine, tranexamic acid a hemostatic agent approved for hemorrhaging in hemophilia, with unapproved uses in cyanide poisioning, hereditary angioedema, hyperfibrinolysis induced hemorrhage, postsurgical hemorrhage and prevention of hemorrhage from cardiovascular instability after coronary artery bypass graft. It is an "inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid." It is similar to, but more potent than aminocaproic acid.[1] It is also used to treat acquired angioedema due to deficiency of complement C1 inhibitor protein.
References
- ↑ Anonymous. cyklokapron (tranexamic acid) injection, solution. U.S. National Library of Medicine. Retrieved on 2009-02-19.
External links
The most up-to-date information about Tranexamic acid and other drugs can be found at the following sites.
- Tranexamic acid - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Tranexamic acid - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Tranexamic acid - Detailed information from DrugBank.